Literature DB >> 27556936

Predicting the Rate of Cognitive Decline in Alzheimer Disease: Data From the ICTUS Study.

Marco Canevelli1, Eirini Kelaiditi, Natalia Del Campo, Giuseppe Bruno, Bruno Vellas, Matteo Cesari.   

Abstract

BACKGROUND: Different rates of cognitive progression have been observed among Alzheimer disease (AD) patients. The present study aimed at evaluating whether the rate of cognitive worsening in AD may be predicted by widely available and easy-to-assess factors.
METHODS: Mild to moderate AD patients were recruited in the ICTUS study. Multinomial logistic regression analysis was performed to measure the association between several sociodemographic and clinical variables and 3 different rates of cognitive decline defined by modifications (after 1 year of follow-up) of the Mini Mental State Examination (MMSE) score: (1) "slow" progression, as indicated by a decrease in the MMSE score ≤1 point; (2) "intermediate" progression, decrease in the MMSE score between 2 and 5 points; and (3) "rapid" progression, decrease in the MMSE score ≥6 points.
RESULTS: A total of 1005 patients were considered for the present analyses. Overall, most of the study participants (52%) exhibited a slow cognitive course. Higher ADAS-Cog scores at baseline were significantly associated with both "intermediate" and "rapid" decline. Conversely, increasing age was negatively associated with "rapid" cognitive worsening.
CONCLUSIONS: A slow progression of cognitive decline is common among AD patients. The influence of age and baseline cognitive impairment should always be carefully considered when designing AD trials and defining study populations.

Entities:  

Mesh:

Year:  2016        PMID: 27556936     DOI: 10.1097/WAD.0000000000000124

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  5 in total

Review 1.  Alzheimer's Disease: Epidemiology and Clinical Progression.

Authors:  Amir Abbas Tahami Monfared; Michael J Byrnes; Leigh Ann White; Quanwu Zhang
Journal:  Neurol Ther       Date:  2022-03-14

2.  Genome-wide association study of rate of cognitive decline in Alzheimer's disease patients identifies novel genes and pathways.

Authors:  Richard Sherva; Alden Gross; Shubhabrata Mukherjee; Ryan Koesterer; Philippe Amouyel; Celine Bellenguez; Carole Dufouil; David A Bennett; Lori Chibnik; Carlos Cruchaga; Jorge Del-Aguila; Lindsay A Farrer; Richard Mayeux; Leanne Munsie; Ashley Winslow; Stephen Newhouse; Andrew J Saykin; John S K Kauwe; Paul K Crane; Robert C Green
Journal:  Alzheimers Dement       Date:  2020-06-23       Impact factor: 16.655

3.  Association between Peripheral Leptin and Adiponectin Levels and Cognitive Decline in Patients with Neurocognitive Disorders ≥65 Years.

Authors:  Thomas Gilbert; Sylvain Roche; Emilie Blond; Jean-Yves Bar; Jocelyne Drai; Charlotte Cuerq; Marine Haution-Bitker; René Ecochard; Marc Bonnefoy
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

4.  Assessment of need and practice for assistive technology and telecare for people with dementia-The ATTILA (Assistive Technology and Telecare to maintain Independent Living At home for people with dementia) trial.

Authors:  Kirsty Forsyth; Catherine Henderson; Lucy Davis; Anusua Singh Roy; Barbara Dunk; Eleanor Curnow; Rebecca Gathercole; Natalie Lam; Emma Harper; Iracema Leroi; John Woolham; Chris Fox; John O'Brien; Andrew Bateman; Fiona Poland; Peter Bentham; Alistair Burns; Anna Davies; Richard Gray; Rosie Bradley; Martin Knapp; Stanton Newman; Rupert McShane; Craig Ritchie; Emma Talbot; Emma Hooper; Rachel Winson; Bethany Scutt; Victoria Ordonez; Samantha Nunn; Grace Lavelle; Robert Howard
Journal:  Alzheimers Dement (N Y)       Date:  2019-09-03

5.  Donepezil Treatment for Alzheimer's Disease in Chronic Dialysis Patients.

Authors:  Konstantina G Yiannopoulou; Aikaterini I Anastasiou; Andreas Kyrozis; Ioannis P Anastasiou
Journal:  Case Rep Nephrol Dial       Date:  2019-09-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.